First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate

Parkinson’s disease (PD) is a chronic and progressive movement disorder with the urgent unmet need for efficient symptomatic therapies with fewer side effects. GPR6 is an orphan G-protein coupled receptor (GPCR) with highly restricted expression in dopamine receptor D2-type medium spiny neurons (MSN...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2021-07, Vol.64 (14), p.9875-9890
Hauptverfasser:	Sun, Huikai, Monenschein, Holger, Schiffer, Hans H, Reichard, Holly A, Kikuchi, Shota, Hopkins, Maria, Macklin, Todd K, Hitchcock, Stephen, Adams, Mark, Green, Jason, Brown, Jason, Murphy, Sean T, Kaushal, Nidhi, Collia, Deanna R, Moore, Steve, Ray, William J, English, Nicole Marion, Carlton, Mark Beresford Lewis, Brice, Nicola L
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!